Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
There is currently no drug with pediatric marketing authorization capable of limiting the
advance in bone maturation of children with aggressive adrenarche. Estrogens are the
principal actors involved in bone maturation and premature epiphyseal fusion. Aromatase
inhibitors, used for the treatment of hormone-dependent cancers, block the transformation of
androgens into estrogens. Third generation inhibitors, of which Anastrozole is one, appear to
be well tolerated in children and are sometimes used within the framework of clinical trials
to limit bone maturation and improve prognosis with respect to final size, notably in
children treated with growth hormone (GH) due to a GH deficit. Nevertheless, the data
reported are based on small sample sizes and do not include children with pathological
adrenarche.